Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

Journal of Clinical Oncology

Volumn 22, Issue 19, 2004, Pages 3950-3957

  Rao, S ^a   Cunningham, David ^a   de Gramont, A ^a   Scheithauer, W ^a   Smakal, M ^a   Humblet, Y ^a   Kourteva, G ^a   Iveson, T ^a   Andre, T ^a   Dostalova, J ^a   Illes, A ^a   Belly, R ^a   Perez Ruixo, J J ^a   Park, Y C ^a   Palmer, P A ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; ANTINEOPLASTIC AGENT; FARNESYL TRANS TRANSFERASE; PLACEBO; QUINOLONE DERIVATIVE; TRANSFERASE;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; ADULT; AGED; COLORECTAL TUMOR; DRUG ANTAGONISM; FEMALE; MALE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; QUINOLONES; SURVIVAL RATE;

EID: 5444241523     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.037     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156, 2001
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 16:301-308, 1998
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
6. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
7. Goldberg RM, Morton RF, Sargent DJ: N9741:Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxaliplatin + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an Intergroup study. Proc Am Soc Clin Oncol 22:252, 2003 (abstr 1009)
8. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
9. Forrester K, Almoguera C, Han K, et al: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303, 1987
10. Johnston SRD, Hickish T, Ellis P: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor R115777 in advanced breast cancer. J Clin Oncol 21:2492-2499, 2003
11. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000
12. Crul M, de Klerk GJ, Swart M, et al: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002
13. Schellens JH, de Klerk GJ, Swart M: Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 19:715, 2000 (abstr 715)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Ward R, Hawkins N, O'Grady R, et al: Restriction endonuclease-mediated selective polymerase chain reaction: A novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol 153:373-379, 1998
16. Roberts NJ, Impey HL, Applegate TL, et al: Rapid, sensitive detection of mutant alleles in codon 12 of K-ras by REMS-PCR. Biotechniques 27:418-422, 1999
17. Fuery CJ, Impey HL, Roberts NJ, et al: Detection of rare mutant alleles by restriction endonuclease-mediated selective-PCR: Assay design and optimization. Clin Chem 46:620-624, 2000
18. th Meeting of Population Approach Group in Europe, June 6-7, 2002, Paris, France (abstr 21)
19. End DW, Smets G, Todd AV, et al: Characterization of the antitumour effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137, 2001
20. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumour cell lines. Cancer Res 55:5302-5309, 1995
21. Punt CJ, van Maanen L, Bol CJ, et al: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumours. Anticancer Drugs 12:193-197, 2001
22. Holden SN, Eckhardt SG, Fisher SA: Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies. Proc Am Soc Clin Oncol 20:316, 2001 (abstr 316)
23. Verweij J, Kehrer DF, Planting A: Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 20:319, 2001 (abstr 319)
24. Verslype C, Van Steenbergen W, Humblet Y: Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 20:681, 2001 (abstr 681)
25. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukaemias: A phase 1 clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
26. Harousseau JL, Stone R, Thomas X: Interim results from a phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute rnyelogenous leukaemia. Proc Am Soc Clin Oncol 21:265, 2002 (abstr 265)
27. Cloughesy TF, Kuhn J, Wen P: Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): A North American Brain Tumour Consortium (NABTC) report. Proc Am Soc Clin Oncol 21:80a, 2002 (abstr 317)